Takashi M, Zhu Y, Hasegawa S, Kato K
Department of Urology, Nagoya University School of Medicine, Japan.
Urol Int. 1992;48(2):144-8. doi: 10.1159/000282318.
We determined the serum levels of the creatine kinase B subunit (CK-B) by an enzyme immunoassay method in patients with renal cell carcinoma (RCC) and benign renal diseases. Eighteen of 76 patients with RCC (24%) had elevated serum CK-B levels. The positive rates were 29% in stage I, 13% in stage II, 15% in stage III, and 27% in stage IV. In all 9 patients whose serum CK-B levels were serially measured and had been elevated before operation, the CK-B levels were reduced to the normal range after nephrectomy. These findings indicate that serum CK-B is a useful biomarker for monitoring the clinical course for a limited number of RCC patients, but is not a marker for diagnosis and staging. Concentrations of CK-B in RCC tissues were significantly lower than those of normal kidney. A high rate of cell turnover in tumor tissues might entail the higher level of serum CK-B in patients with RCC.
我们采用酶免疫测定法测定了肾细胞癌（RCC）患者和良性肾脏疾病患者血清肌酸激酶B亚基（CK-B）的水平。76例RCC患者中有18例（24%）血清CK-B水平升高。I期患者的阳性率为29%，II期为13%，III期为15%，IV期为27%。在所有9例术前血清CK-B水平连续测定且升高的患者中，肾切除术后CK-B水平降至正常范围。这些发现表明，血清CK-B是监测少数RCC患者临床病程的有用生物标志物，但不是诊断和分期的标志物。RCC组织中CK-B的浓度显著低于正常肾脏。肿瘤组织中较高的细胞更新率可能导致RCC患者血清CK-B水平升高。
